Century Therapeutics Appoints Joseph Truitt to Board

What Happened

• Century Therapeutics (IPSC) filed an 8‑K on September 9, 2026 announcing that its Board increased from six to seven directors and appointed Joseph Truitt as a Class I director effective that date. Mr. Truitt will serve on the Compensation Committee and his term expires at the 2028 Annual Meeting of Stockholders. The filing also attaches a press release (Exhibit 99.1) under Regulation FD.

Key Details

• Appointment date: September 9, 2026; Board size increased from 6 to 7.
• Term & role: Class I director, term through the 2028 Annual Meeting; member of the Compensation Committee.
• Compensation: Initial option grant to purchase 148,000 shares under the 2021 Equity Incentive Plan, vesting monthly over 36 months; annual cash retainer of $40,000.
• Background & independence: Mr. Truitt (age 62) is CEO of iECURE, has prior CEO and board roles at multiple biotech firms, and has been determined by the Board to be an independent director. The company entered into a standard indemnification agreement; no related-party transactions or family relationships were reported.

Why It Matters

• New independent directors can affect oversight and strategy; Mr. Truitt brings biotech executive and board experience that may influence compensation and corporate governance given his assignment to the Compensation Committee. The equity and cash retainer are standard non-employee director pay and could lead to incremental dilution if options are exercised. The filing confirms the change was routine (no related-party issues) and includes a public press release for investors seeking more detail.